Yukiya Amano, director general of the International Atomic Energy Agency, visited a new nuclear medicine manufacturing plant in Australia that will soon produce international-scale supplies of molybdenum-99 (Mo-99). Ansto (Australian Nuclear Science and Technology Organization) briefed Amano on the status of construction of the plant at its Lucas Heights site near Sydney.

The plant is expected to produce Mo-99 at a capacity of 10 million doses a year in order to supply 25% of global demand for nuclear medicine by the end of 2017. The $168.8 million project is in the final phases of construction, having received its engine room including ten hot cells, and aims, by the end of next year, to reach full scale production.

To read more please visit: http://www.world-nuclear-news.org/RS-IAEA-chief-witnesses-progress-of-Australian-medicine-plant-08081601.html

Source: World Nuclear News